We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

GRI Bio Inc (GRI) USD0.0001

Sell:$0.77 Buy:$0.78 Change: $0.0162 (2.15%)
Market closed |  Prices as at close on 24 December 2024 | Switch to live prices |
Sell:$0.77
Buy:$0.78
Change: $0.0162 (2.15%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 24 December 2024 | Switch to live prices |
Sell:$0.77
Buy:$0.78
Change: $0.0162 (2.15%)
Market closed |  Prices as at close on 24 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

GRI Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic, and autoimmune disorders. Its therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. Its lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as an oral therapeutic for the treatment of idiopathic pulmonary fibrosis (IPF). Its product candidate portfolio also includes GRI-0803 and a proprietary library of 500+ compounds. The Company is developing GRI-0803 for the treatment of autoimmune disorders, with much of its preclinical work in systemic lupus erythematosus disease (SLE) or lupus and multiple sclerosis (MS).

Contact details

Address:
2223 Avenida De La Playa, Suite 208
LA JOLLA
92037
United States
Telephone:
+1 (619) 4001171
Website:
https://www.gribio.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
GRI
ISIN:
US3622AW3040
Market cap:
$6.88 million
Shares in issue:
8.93 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • W. Marc Hertz
    President, Chief Executive Officer, Director
  • Leanne Kelly
    Chief Financial Officer
  • Vipin Chaturvedi
    Chief Scientific Officer
  • Albert Agro
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.